Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Intelligence Hub
News
Changes
Search
Log in
Get Started
VEPPANU (VEPDEGESTRANT) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
VEPPANU
NDA
VEPDEGESTRANT | N219835 | ARVINAS OPERATIONS INC
2 strengths
3 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
3 unique patents, 1 exclusivity by expiration date
All strengths
100MG
200MG
Active (3)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
Today
10647698
Jan. 30, 2038
10899742
Dec. 1, 2037
11597720
Dec. 1, 2037
NCE
May. 1, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 100MG
RLD
3 patents
1 exclusivity
▴
TABLET;ORAL | Approved: May 1, 2026
Patents (3)
· 2 use codes
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10647698
Jan 30, 2038
—
Yes
Yes
—
—
10899742
Dec 1, 2037
—
—
—
U-4278
TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
—
11597720
Dec 1, 2037
—
Yes
Yes
U-4278
TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
—
Exclusivities (1)
Code
Date
Status
NCE
May 1, 2031
Active
#002 — 200MG
RLD
3 patents
1 exclusivity
▾
TABLET;ORAL | Approved: May 1, 2026